Abstract
Introduction: Total bilirubin (TB) is a major prognosis predictor representing liver failure in patients with acute on chronic liver failure (ACLF). However, the cutoff value of TB for liver failure and whether the same cutoff could be applied in both cirrhotic and non-cirrhotic patients remain controversial. There is a need to obtain the quantitative correlation between TB and short-term mortality via evidence-based methods, which is critical in establishing solid ACLF diagnostic criteria.
Methods: Patients hospitalized with cirrhosis or advanced fibrosis (FIB-4 > 1.45) were studied. TB and other variables were measured at baseline. The primary outcome was 90-day transplantation-free mortality. Multi-variable Cox proportional hazard model was used to present the independent risk of mortality due to TB. Generalized additive model and second derivate (acceleration) were used to plot the “TB-mortality correlation curves.” The mathematical (maximum acceleration) and clinical (adjusted 28-day transplantation-free mortality rate reaching 15%) TB cutoffs for liver failure were both calculated.
Results: Among the 3,532 included patients, the number of patients with cirrhosis and advanced fibrosis were 2,592 and 940, respectively, of which cumulative 90-day mortality were 16.6% (430/2592) and 7.4% (70/940), respectively. Any increase of TB was found the independent risk factor of mortality in cirrhotic patients, while only TB >12 mg/dL independently increased the risk of mortality in patients with advanced fibrosis. In cirrhotic patients, the mathematical TB cutoff for liver failure is 14.2 mg/dL, with 23.3% (605/2592) patients exceeding it, corresponding to 13.3 and 25.0% adjusted 28- and 90-day mortality rate, respectively. The clinical TB cutoff for is 18.1 mg/dL, with 18.2% (471/2592) patients exceeding it. In patients with advanced fibrosis, the mathematical TB cutoff is 12.1 mg/dL, 33.1% (311/940) patients exceeding it, corresponding to 2.9 and 8.0% adjusted 28- and 90-day mortality rate, respectively; the clinical TB cutoff was 36.0 mg/dL, 1.3% (12/940) patients above it.
Conclusion: This study clearly demonstrated the significantly different impact of TB on 90-day mortality in patients with cirrhosis and advanced fibrosis, proving that liver failure can be determined by TB alone in cirrhosis but not in advanced fibrosis. The proposed TB cutoffs for liver failure provides solid support for the establishment of ACLF diagnostic criteria.
Introduction
The disease burden of acute on chronic liver failure (ACLF) is enormous. It affects 10–35% hospitalized patients with cirrhosis (–) and a considerable part of patients with non-cirrhotic chronic liver diseases (, ). ACLF is associated with sharply increased risk of short-term mortality (, –) and heavy financial costs (, ). The presence of organ failure is a prerequisite for the diagnosis of ACLF (, , ). In East Asia, where hepatitis B virus (HBV) infection is highly endemic (, ), liver failure is the most common type of organ failure (, ). Therefore, a clear definition of liver failure is essential in ACLF diagnosis in HBV high-endemic areas.
Though high total bilirubin (TB) has been confirmed to be strongly associated with poor liver preservation and high short-term mortality (, , , ), there are fierce controversies between the East and the West on the application of TB in the diagnosis of liver failure. The European Association for the Study of the Liver - Chronic Liver Failure (EASL-CLIF) defined liver failure using TB alone (TB > 12 mg/dL) (, ). While in Asia, liver failure was defined more frequently with a combination of TB and international normalized ratio (INR), such as the Asia-Pacific Association for the Study of the Liver (APASL) criteria (TB > 5 mg/dL and INR > 1.5) () and the Chinese Group on the Study of Severe Hepatitis B (COSSH) criteria (TB > 12 mg/dL and INR > 1.5) (). The inequality was mainly due to whether patients with non-cirrhotic chronic liver diseases included in the respective study (, , , , ).
The key to resolving these controversies on the definition of liver failure is to clarify whether the liver failure of cirrhosis and non-cirrhotic chronic liver diseases (mainly advanced fibrosis) can be diagnosed by the same criteria. Given the absence of studies evaluating this specific issue, we aimed to describe the quantitative correlation between the baseline TB level and the 90-day mortality among hospitalized patients with cirrhosis and advanced fibrosis, respectively. The detailed and intuitive presentation of this correlation is crucial to define liver failure and establish the solid ACLF diagnostic criteria.
Materials and Methods
Study Design, Setting, and Oversight
We combined the data from two prospective observational cohorts of the Chinese AcuTe on CHronic LIver FailurE (CATCH-LIFE) study: the CATCH-LIFE investigation cohort (NCT02457637) involving 14 hospitals throughout China, enrollment occurred from January 2015 to December 2016; and the CATCH-LIFE validation cohort (NCT03641872), involving 13 hospitals throughout China, enrollment occurred from September 2018 to March 2019. All participants were followed-up for at least 90 days. The study protocols and baseline characteristics have been described in detail elsewhere (, ). The medical ethics boards of Shanghai Renji Hospital (the lead center of the CATCH-LIFE study), approved the study [ethics code: (2014)148 k and (2016)142 k]. Written informed consent were obtained from every participant or his/her legal surrogates before enrollment.
Study Population
Eligible patients were required with cirrhosis or advanced fibrosis hospitalized with at least one of the following criteria: (1) with acute decompensations (ADs), including overt ascites (), gastrointestinal bleeding, hepatic encephalopathy (HE) (), bacterial infection, or jaundice (TB > 5 mg/dL)] within 1 month before enrollment; (2) with acute liver injury, including alanine aminotransferase (ALT), or aspartate aminotransferase (AST) >3 upper limitation of normal level or total bilirubin (TB) >2 upper limitation of normal level within recent 1 week before enrollment.
Patients with cirrhosis and advanced fibrosis were divided into two groups for comparison. Cirrhosis was diagnosed according to the signs of dysmorphia and relation to liver fibrosis and portal hypertension in the imaging examination (computerized tomography, magnetic resonance imaging or abdominal ultrasound) after enrolment. The cirrhotic patients with a history of decompensation at least 1 month ago are defined to have decompensated cirrhosis, and other cirrhotic patients without any history of decompensation (including the patients hospitalized due to the first episode of decompensation events) are defined to have compensatory cirrhosis. Non-cirrhotic patients with a fibrosis-4 (FIB-4) score () < 1.45 were excluded to rule-out those who with merely mild or no fibrosis.
Exposure and Outcomes
The primary exposure was TB level (mg/dL), which was measured at admission. Other clinical data were measured and collected at admission as well, including demographics (age, sex), etiology of underlying liver diseases (HBV related, alcohol related or others), complications (type of ADs), laboratory findings and severity scores [the model of end-stage liver diseases [MELD] (), MELD-Sodium (), and Child-Turcotte-Pugh ()].
The primary outcome was the 90-day mortality (transplantation-free). The patients who received liver transplantation (LT) within 90 days were excluded to present the correlation between baseline TB level and patients' natural 90-day prognosis.
Statistical Analysis
Continuous variables were summarized by mean and standard deviation (SD) or median or inter-quartile range (IQR) based on their distribution. Categorical variables were summarized by frequency and proportion [with 95% confidence interval (CI)].
The correlation between TB and 90-day mortality were analyzed using a multivariable Cox proportional hazard (COXPH) model, adjusting for important risk factors and potential confounders, including age, sex, etiologies of underlying chronic liver diseases, presence or absence of overt ascites, gastrointestinal bleeding and bacterial infection, the grades of HE, the level of INR, creatinine, ALT, and serum sodium. The risk of 90-day mortality was expressed as a continuous variable with hazard ratios (HRs) calculated per mg/dL increment of TB, and as a categorical variable based on different range of TB levels as following: <2, 2–5, 5–8, 8–12, 12–16, 16–20, and >20 mg/dL; the patients with lowest TB (<2 mg/dL) were taken as the reference.
The non-lineal relationship in 90-day mortality over the range of TB level (0–50 mg/dL) was plotted as a “TB-mortality correlation curve.” The estimated mortality corresponding to the TB values in the curves was adjusted for above listed confounding factors by the generalized additive model (GAM) () to present the independent impact of TB on mortality. Spline () was taken as connection function in GAM and the smoothing parameters were chosen to optimize the Akaike Information Criterion. Second derivative (acceleration) () of TB to mortality was used to describe the non-lineal relationship.
Finally, based on the multivariable adjusted TB-mortality correlation curves, the TB values that correspond to the inflection points (maximum of acceleration) of the curves would be taken as the mathematical cutoff. Additionally, the TB value that correspond to adjusted 28-day transplantation-free mortality reaching 15% (the definition of EASL-CLIF) () would be calculated as well and taken as clinical cutoff for liver failure.
The analysis above mentioned will be performed in patients with cirrhosis and advanced fibrosis, respectively to compare the characteristics of them. The software environment R 4.0.0 and MATLAB 2016b were used for the analysis. The R package gam was used for the GAM fitting and the MATLAB tool box curve fitting was used for curve fitting and second derivative calculation. All tests were 2-sided with α = 0.05.
Results
Enrollment and Baseline Characteristics
A total of 3,532 patients were included in this analysis (Figure 1). Among them, 2,592 (73.4%) patients had cirrhosis (including 1,532 compensated and 1,060 decompensated), and 940 (26.6%) patients had advanced fibrosis. Patients underwent LT within 90 days (n = 246), with non-cirrhosis chronic liver diseases and a FIB-4 score < 1.45 (n = 178), or with missing TB values (n = 5), or FIB-4 score (n = 9) were excluded. All patients included finished the 90-day follow-up. The cumulative 90-day transplantation-free mortality of the patients with cirrhosis and advanced fibrosis were 16.6% (430/2592) (Table 1) and 7.4% (70/940), respectively (Table 2). Demographic, clinical characteristics and 90-day transplantation-free mortality of patients with cirrhosis and advanced fibrosis are presented in Tables 1, 2, respectively according to different TB level. The pattern of missing data can be found in Figure 2.
Figure 1
Table 1
| Variable | 0<TB≤2 | 2<TB≤5 | 5<TB≤8 | 8<TB≤12 | 12<TB≤16 | 16<TB≤20 | 20<TB |
|---|---|---|---|---|---|---|---|
| N = 839 | N = 601 | N = 215 | N = 220 | N = 172 | N = 139 | N = 406 | |
| Demographics | |||||||
| Age, mean (SD) | 54.4 (11.4) | 52.2 (11.0) | 51.1 (11.4) | 50.8 (11.4) | 49.0 (11.1) | 48.1 (10.4) | 48.3 (11.3) |
| Gender, No. (%) | 553 (65.9) | 439 (73.0) | 149 (69.3) | 161 (73.2) | 124 (72.1) | 112 (80.6) | 351 (86.5) |
| Etiology, No. (%) | |||||||
| HBV | 486 (57.9) | 366 (60.9) | 131 (60.9) | 123 (55.9) | 118 (68.6) | 96 (69.1) | 307 (75.6) |
| Alcoholic | 101 (12.0) | 78 (13.0) | 29 (13.5) | 36 (16.4) | 16 (9.3) | 12 (8.6) | 27 (6.7) |
| Others | 252 (30.0) | 157 (26.1) | 55 (25.6) | 61 (27.7) | 38 (22.1) | 31 (22.3) | 72 (17.7) |
| Complications, No. (%) | |||||||
| Ascites | 481 (57.3) | 369 (61.4) | 131 (60.9) | 138 (62.7) | 104 (60.5) | 98 (70.5) | 285 (70.2) |
| Gastrointestinal bleeding | 342 (40.8) | 99 (16.5) | 26 (12.1) | 13 (5.9) | 10 (5.8) | 4 (2.9) | 20 (4.9) |
| Bacterial infection | 134 (16.0) | 128 (21.3) | 58 (27.0) | 75 (34.1) | 58 (33.7) | 44 (31.7) | 196 (48.3) |
| Hepatic encephalopathy | |||||||
| Not overt | 805 (95.9) | 564 (93.8) | 197 (91.6) | 205 (93.2) | 161 (93.6) | 136 (97.8) | 350 (86.2) |
| Grade 2 | 25 (3.0) | 26 (4.3) | 10 (4.7) | 9 (4.1) | 10 (5.8) | 2 (1.4) | 37 (9.1) |
| Grade 3 | 7 (0.8) | 6 (1.0) | 8 (3.7) | 4 (1.8) | 0 (0.0) | 1 (0.7) | 14 (3.4) |
| Grade 4 | 2 (0.2) | 5 (0.8) | 0 (0.0) | 2 (0.9) | 1 (0.6) | 0 (0.0) | 5 (1.2) |
| Laboratory results, median (IQR) | |||||||
| Hemoglobin, g/L | 97.0 (75.0, 118.0) | 113.0 (95.0, 128.0) | 105.0 (88.5, 122.0) | 110.2 (89.0, 131.9) | 115.5 (96.8, 129.0) | 118.0 (107.2, 132.0) | 119.0 (103.0, 133.4) |
| White blood cell, 109/L | 3.9 (2.6, 5.5) | 4.1 (3.0, 6.0) | 4.8 (3.4, 6.4) | 5.3 (3.7, 7.0) | 5.7 (4.1, 7.8) | 6.1 (4.7, 8.1) | 7.1 (5.0, 10.1) |
| Platelet, 109/L | 76.0 (51.0, 122.0) | 64.0 (42.9, 98.0) | 71.0 (46.0, 106.5) | 76.0 (48.9, 118.5) | 80.5 (54.0, 123.2) | 92.0 (63.5, 128.0) | 85.0 (58.0, 121.0) |
| International normalized ratio | 1.3 (1.1, 1.4) | 1.5 (1.3, 1.6) | 1.6 (1.4, 1.9) | 1.7 (1.4, 2.1) | 1.9 (1.5, 2.4) | 1.9 (1.5, 2.4) | 2.1 (1.6, 2.7) |
| Creatinine, mg/dL | 0.8 (0.7, 1.0) | 0.8 (0.6, 0.9) | 0.7 (0.6, 0.9) | 0.7 (0.6, 1.0) | 0.8 (0.6, 1.0) | 0.8 (0.6, 1.0) | 0.9 (0.7, 1.2) |
| Albumin, g/L | 31.9 (27.6, 36.0) | 29.2 (25.2, 33.1) | 28.3 (24.5, 34.0) | 29.7 (26.3, 33.4) | 29.8 (26.6, 33.0) | 29.6 (26.2, 33.0) | 31.0 (27.9, 34.0) |
| Alanine transaminase, IU/L | 28.0 (17.7, 51.5) | 45.3 (27.0, 89.6) | 58.1 (31.0, 151.4) | 100.6 (33.2, 391.9) | 102.4 (45.5, 372.6) | 206.3 (85.3, 566.6) | 159.3 (61.5, 385.3) |
| Aspartate transaminase, IU/L | 37.0 (24.6, 62.9) | 65.0 (42.0, 116.6) | 92.3 (51.0, 179.0) | 126.3 (62.9, 330.0) | 145.4 (77.3, 291.5) | 191.8 (110.1, 429.3) | 177.9 (100.8, 332.8) |
| Sodium, mmol/L | 139.7 (137.0, 141.8) | 138.6 (135.8, 141.0) | 137.4 (134.9, 140.0) | 137.3 (133.4, 139.5) | 137.3 (133.3, 139.8) | 136.9 (133.9, 138.9) | 135.0 (131.0, 138.0) |
| Score, mean (SD) | |||||||
| MELD | 9.7 (4.0) | 14.4 (3.9) | 18.2 (5.0) | 20.8 (4.6) | 23.0 (4.8) | 25.1 (5.1) | 28.6 (5.7) |
| MELD-Na | 10.5 (5.1) | 15.7 (5.1) | 19.6 (6.6) | 22.6 (4.8) | 24.5 (5.5) | 26.6 (4.9) | 30.0 (5.3) |
| CTP | 7.3 (1.4) | 9.4 (1.5) | 10.2 (1.6) | 10.3 (1.7) | 10.5 (1.8) | 10.6 (1.7) | 10.8 (1.7) |
| Transplantation-free mortality | |||||||
| 28-day, No. (%) | 17 (2.0) | 26 (4.3) | 14 (6.5) | 19 (8.6) | 22 (12.8) | 26 (18.7) | 117 (28.8) |
| 90-day, No. (%) | 35 (4.2) | 51 (8.5) | 25 (11.6) | 36 (16.4) | 38 (22.1) | 44 (31.7) | 201 (49.5) |
Comparison of baseline characteristics of patients with cirrhosis based on different level of total bilirubin (mg/dL) at admission.
SD, standard deviation; HBV, hepatitis B virus; IQR, interquartile range; MELD, the model of end-stage liver disease; MELD-Sodium, the model of end-stage liver disease with sodium; CTP, Child-Turcotte-Pugh.
Table 2
| Variable | 0<TB≤2 | 2<TB≤5 | 5<TB≤8 | 8<TB≤12 | 12<TB≤16 | 16<TB≤20 | 20<TB |
|---|---|---|---|---|---|---|---|
| N = 239 | N = 188 | N = 96 | N = 104 | N = 103 | N = 74 | N = 136 | |
| Demographics | |||||||
| Age, mean (SD) | 44.8 (12.7) | 42.1 (11.3) | 41.4 (12.5) | 43.8 (12.0) | 42.5 (11.2) | 43.8 (11.6) | 43.3 (12.5) |
| Gender, No. (%) | 159 (66.5) | 146 (77.7) | 76 (79.2) | 72 (69.2) | 79 (76.7) | 60 (81.1) | 114 (83.8) |
| Etiology, No. (%) | |||||||
| HBV | 160 (66.9) | 133 (70.7) | 71 (74.0) | 77 (74.0) | 86 (83.5) | 47 (63.5) | 113 (83.1) |
| Alcoholic | 9 (3.8) | 5 (2.7) | 3 (3.1) | 2 (1.9) | 2 (1.9) | 2 (2.7) | 2 (1.5) |
| Others | 70 (29.3) | 50 (26.6) | 22 (22.9) | 25 (24.0) | 15 (14.6) | 25 (33.8) | 21 (15.4) |
| Complications, No. (%) | |||||||
| Ascites | 6 (2.5) | 6 (3.2) | 9 (9.4) | 15 (14.4) | 19 (18.4) | 14 (18.9) | 51 (37.5) |
| Bacterial infection | 10 (4.2) | 8 (4.3) | 7 (7.3) | 9 (8.7) | 16 (15.5) | 16 (21.6) | 41 (30.1) |
| Hepatic encephalopathy | |||||||
| Not overt | 239 (100.0) | 188 (100.0) | 96 (100.0) | 104 (100.0) | 99 (96.1) | 72 (97.3) | 122 (89.7) |
| Grade 2 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (1.9) | 0 (0.0) | 8 (5.9) |
| Grade 3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.0) | 2 (2.7) | 4 (2.9) |
| Grade 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.0) | 0 (0.0) | 2 (1.5) |
| Laboratory results, median (IQR) | |||||||
| Hemoglobin, g/L | 141.0 (127.0, 152.0) | 138.0 (128.8, 153.0) | 136.0 (121.5, 145.2) | 136.0 (117.2, 147.0) | 136.0 (124.5, 151.0) | 130.0 (114.8, 142.0) | 128.0 (115.0, 144.0) |
| White blood cell, 109/L | 4.6 (4.0, 5.4) | 4.7 (3.9, 5.9) | 5.2 (4.1, 6.3) | 5.2 (4.2, 6.6) | 6.2 (5.0, 7.6) | 6.6 (5.2, 7.9) | 7.2 (5.7, 9.8) |
| Platelet, 109/L | 147.0 (113.0, 187.2) | 139.5 (103.2, 177.5) | 128.0 (102.0, 168.5) | 136.5 (94.8, 171.2) | 132.0 (98.0, 160.0) | 129.0 (98.0, 173.5) | 122.0 (90.2, 166.0) |
| International normalized ratio | 1.1 (1.0, 1.2) | 1.2 (1.0, 1.3) | 1.3 (1.1, 1.6) | 1.4 (1.1, 1.7) | 1.6 (1.3, 2.1) | 1.5 (1.2, 2.0) | 1.8 (1.5, 2.5) |
| Creatinine, mg/dL | 0.7 (0.6, 0.9) | 0.8 (0.7, 0.9) | 0.7 (0.6, 0.8) | 0.7 (0.6, 0.9) | 0.7 (0.6, 0.8) | 0.8 (0.7, 0.9) | 0.8 (0.6, 1.0) |
| Albumin, g/L | 40.1 (36.8, 43.5) | 38.3 (34.2, 42.0) | 35.9 (33.0, 39.5) | 34.5 (31.8, 37.9) | 33.2 (30.0, 37.4) | 32.7 (29.3, 36.2) | 32.2 (29.9, 35.6) |
| Alanine transaminase, IU/L | 408.0 (184.0, 751.5) | 790.0 (383.5, 1137.0) | 832.0 (310.5, 1360.0) | 653.0 (301.1, 1331.2) | 639.4 (273.2, 1275.5) | 509.9 (147.2, 952.0) | 302.4 (145.0, 818.1) |
| Aspartate transaminase, IU/L | 248.0 (144.0, 431.2) | 428.9 (220.0, 750.2) | 535.5 (223.1, 1007.2) | 508.4 (267.7, 908.2) | 433.0 (197.0, 949.7) | 284.6 (153.7, 680.0) | 207.1 (144.8, 571.2) |
| Sodium, mmol/L | 140.4 (138.0, 142.0) | 140.0 (138.0, 141.4) | 139.0 (136.5, 140.8) | 139.0 (136.2, 140.8) | 138.0 (136.0, 140.0) | 137.0 (135.0, 139.0) | 137.2 (135.0, 140.0) |
| Score, mean (SD) | |||||||
| MELD | 8.2 (2.8) | 12.4 (3.3) | 16.6 (3.0) | 19.1 (3.9) | 21.5 (4.2) | 23.1 (4.8) | 26.8 (5.7) |
| MELD-Na | 8.1 (4.0) | 12.7 (3.9) | 17.5 (3.5) | 20.1 (4.0) | 22.4 (4.3) | 24.3 (4.8) | 27.7 (5.6) |
| CTP | 5.3 (0.8) | 6.9 (1.0) | 7.8 (1.0) | 8.3 (1.3) | 8.7 (1.6) | 8.9 (1.7) | 9.6 (1.9) |
| Transplantation-free mortality | |||||||
| 28-day, No. (%) | 0 (0.0) | 1 (0.5) | 0 (0.0) | 1 (1.0) | 7 (6.8) | 4 (5.4) | 27 (19.9) |
| 90-day, No. (%) | 3 (1.3) | 2 (1.1) | 2 (2.1) | 5 (4.8) | 10 (9.7) | 11 (14.9) | 37 (27.2) |
Comparison of baseline characteristics of patients with advanced fibrosis based on different level of total bilirubin (mg/dL) at admission.
SD, standard deviation; HBV, hepatitis B virus; IQR, interquartile range; MELD, the model of end-stage liver disease; MELD-Sodium, the model of end-stage liver disease with sodium; CTP, Child-Turcotte-Pugh.
Figure 2
Any Increase of TB Independently Increased the Mortality Risk in Cirrhosis
In patients with cirrhosis, any increase in TB, either expressed as a continuous variable or categorical variable, was the risk factor of 90-day mortality in all univariable and multivariable-adjusted analysis. The full-adjusted HR was 1.060 (95% CI, 1.051–1.069) per 1 mg/dL increase of TB (Table 3). Categorical-variable analysis showed that compared with the cirrhotic patients with normal TB (<2 mg/dL), the HRs were significantly higher in patients within any other categories of elevated TB (p<0.001 for all). Moreover, the HRs were positively correlated with the TB level of patients p (for trend = 0.002).
Table 3
| Total bilirubin (mg/dL) | Number of patients | Number of death (%) | Hazard ratio of transplantation-free mortality (95% CI), p-value | ||
|---|---|---|---|---|---|
| Unadjusted | Adjusted* | ||||
| As a continuous variable | 2,592 | 430 (15.3) | 1.077 (1.070–1.084), <0.001 | 1.060 (1.051–1.069), <0.001 | |
| As a categorical variable | 0–2 | 839 | 35 (3.9) | 1 (Reference) | 1 (Reference) |
| 2–5 | 601 | 51 (8) | 2.081 (1.354–3.200), 0.001 | 2.120 (1.364–3.295), 0.001 | |
| 5–8 | 215 | 25 (10.9) | 2.915 (1.745–4.870), <0.001 | 2.520 (1.467–4.331), 0.001 | |
| 8–12 | 220 | 36 (15.7) | 4.170 (2.619–6.640), <0.001 | 3.527 (2.154–5.776), <0.001 | |
| 12–16 | 172 | 38 (20.5) | 5.858 (3.701–9.273), <0.001 | 4.808 (2.934–7.878), <0.001 | |
| 16–20 | 139 | 44 (28.8) | 8.988 (5.765–14.012), <0.001 | 7.927 (4.861–12.928), <0.001 | |
| Over 20 | 406 | 201 (42.8) | 16.171 (11.289–23.166), <0.001 | 10.422 (6.874–15.802), <0.001 | |
| P-value for trend | 0.004 | <0.001 | |||
The unadjusted and adjusted hazard ratios of 90-day transplantation-free mortality due to total bilirubin in patients with cirrhosis.
Adjusted for age, gender, etiology, hepatic encephalopathy grade, infection, ascites, gastrointestinal bleeding, international normalized ratio, creatinine, serum sodium and alanine transaminase.
The Mortality Risk Increased only if TB Is >12 mg/dL in Advanced Fibrosis
In patients with advanced fibrosis, though as a continuous variable, higher TB was also independently associated with 90-day mortality overall [adjusted HR of 1.080 per 1 mg/dL increase of TB, (95% CI, 1.049–1.112)]. Interestingly, categorical-variable analysis demonstrated that these effects were primarily driven by TB over 12 mg/dL (Table 4), any TB categories <12 mg/dL was not the independent risk factor of mortality. Besides the qualitative p-values, it can be found that compared to the HRs of the patients with TB of 2–5 mg/dL [0.802 (95% CI, 0.130–4.956), p = 0.812], 5–8 mg/dL [1.443 (95% CI, 0.237–8.803), p = 0.691], and 8–12 mg/dL [1.866 (95% CI, 0.401–8.681), p = 0.426], the HR in patients with TB of 12–16 mg/dL markedly elevated to 4.186 [(95% CI 1.070–16.371), p = 0.040], suggesting a threshold effect within the range.
Table 4
| Total bilirubin (mg/dL) | Number of patients | Number of death (%) | Hazard ratio of transplantation-free mortality (95% CI), p-value | ||
|---|---|---|---|---|---|
| Unadjusted | Adjusted* | ||||
| As a continuous variable | 940 | 70 (7.3) | 1.109 (1.087–1.131), <0.001 | 1.080 (1.049–1.112), <0.001 | |
| As a categorical variable | 0–2 | 239 | 3 (1.3) | 1 (Reference) | 1 (Reference) |
| 2–5 | 188 | 2 (1.1) | 0.845 (0.141–5.056), 0.854 | 0.802 (0.130–4.956), 0.812 | |
| 5–8 | 96 | 2 (2.1) | 1.653 (0.276–9.895), 0.582 | 1.443 (0.237–8.803), 0.691 | |
| 8–12 | 104 | 5 (4.7) | 3.887 (0.929–16.267), 0.063 | 1.866 (0.401–8.681), 0.426 | |
| 12–16 | 103 | 10 (9.5) | 8.131 (2.238–29.545), 0.001 | 4.186 (1.070–16.371), 0.040 | |
| 16–20 | 74 | 11 (14.5) | 12.606 (3.517–45.188), <0.001 | 5.829 (1.476–23.026), 0.012 | |
| Over 20 | 136 | 37 (25.9) | 25.624 (7.899–83.118), <0.001 | 8.455 (2.358–30.312), 0.001 | |
| P-value for trend | 0.008 | 0.002 | |||
The unadjusted and adjusted hazard ratios of 90-day transplantation-free mortality due to total bilirubin in patients with advanced fibrosis.
Adjusted for age, gender, etiology, hepatic encephalopathy grade, infection, ascites, international normalized ratio, creatinine, serum sodium, and alanine transaminase.
Liver Failure Can Be Defined by TB Alone in Cirrhosis
Through the GAM and spline, we intuitively plotted the relationship between TB and multivariable-adjusted 90-day transplantation-free mortality. Both the TB-mortality correlation curves of cirrhosis and advanced fibrosis were monotonically increasing. However, the rate of change of 90-day transplantation-free mortality per mg/dL of TB was not a constant, implying the existence of non-lineal effects.
The TB-mortality correlation curve of cirrhosis (Figure 3A) was S-shaped and can be roughly divided into three parts by two inflection points (TB of 14.2 and 24.8 mg/dL). The two points, respectively correspond to the maximum and minimum values (peak and valley in Figure 3B of the second derivative (acceleration) of the mortality relative to the change in TB. To be specific, when TB was between 0 and 14.2 mg/dL, the mortality acceleratingly increases with TB. When TB was between 14.2 and 24.8 mg/dL, the absolute mortality brought by per mg/dL increase of TB is the largest. When TB exceeds 24.8 mg/dL, the increase of mortality slows down, showing a saturation effect.
Figure 3
The mathematical TB cutoff was 14.2 mg/dL, with 23.3% (605/2592) patients exceeding the cutoff. The corresponding adjusted 28- and 90-day transplantation-free mortality were 13.3 and 25.0%, respectively. Moreover, the clinical TB cutoff was 18.1 mg/dL Figure 4A, with 18.2% (471/2592) patients exceeding the cutoff. The corresponding adjusted 90-day transplantation-free mortality was 32.7%. If take the TB of 24.8 mg/dL (the valley in Figure 3B) as a cutoff, 10.3% (268/2592) patients have TB higher than the cutoff, corresponding to 19.2 and 44.8% of adjusted 28- and 90-day transplantation-free mortality, respectively.
Figure 4
We furtherly plotted the TB-mortality correlation curves of patients with compensated cirrhosis (Figures 5A,B) and decompensated cirrhosis (Figures 5C,D). The trends of the two curves were similar, and both have two inflection points. Compared with the curve of compensated cirrhosis, the curve of decompensated cirrhosis is closer to linearity, and the TB value corresponding to the two inflection points were smaller (7.5 vs. 16.0 mg/dL, and 18.6 vs. 26.0 mg/dL).
Figure 5
Liver Failure Is Insufficient to Be Defined by TB Alone in Advanced Fibrosis
The independent effects of TB on mortality in patients with advanced fibrosis (Figure 6A) are significantly different from that in cirrhotic patients, either compensated or decompensated (Figure 7). Compared with the TB-mortality correlation curve of cirrhosis, besides the lower overall mortality, there is only one inflection point (the peak in Figure 6B, 12.1 mg/dL) in the TB-mortality correlation curve of advanced fibrosis, dividing the curve into two parts. The TB-mortality correlation curve is almost horizontal when TB is below 12.1 mg/dL. While with TB exceeding 12.1 mg/dL, mortality rate is positively and linearly related to TB. It was consistent with the findings from the COXPH model presented in Table 4.
Figure 6
Figure 7
The mathematical TB cutoff was 12.1 mg/dL, with 33.1% (311/940) patients with advanced fibrosis exceeding the cutoff, corresponding to 2.9 and 8.0% adjusted 28- and 90-day transplantation-free mortality, respectively. The clinical TB cutoff was calculated to be 36.0 mg/dL (Figure 4B). With this cutoff, only 1.3% (12/940) patients could be stratified with a higher TB, among which 22.1% died during 90 days (Table 5).
Table 5
| Meaning of the TB cutoff | Value of the cutoff | Percentage of patients with TB exceeding the cutoff | Corresponding adjusted transplantation-free mortality | ||
|---|---|---|---|---|---|
| 28 days | 90 days | ||||
| Cirrhosis | Peak of acceleration curve (mathematical cutoff) | 14.2 mg/dL | 23.3% (605/2592) | 13.3% | 25.0% |
| Valley of acceleration curve | 24.8 mg/dL | 10.3% (268/2592) | 19.1% | 44.8% | |
| Reaching 15% 28-day transplantation-free mortality (clinical cutoff) | 18.1 mg/dL | 18.2% (471/2592) | 15.0% | 32.7% | |
| Advanced fibrosis | Peak of acceleration curve (mathematical cutoff) | 12.1 mg/dL | 33.1% (311/940) | 2.9% | 8.0% |
| Reaching 15% 28-day transplantation-free mortality (clinical cutoff) | 36.0 mg/dL | 1.3% (12/940) | 15.0% | 22.1% | |
The multivariable adjusted 28-day and 90-day mortality based on the calculated the mathematical and clinical TB cutoffs for liver failure.
TB, total bilirubin.
Discussion
The present prospective study with large sample size first time established the respective TB cutoffs for liver failure in cirrhosis and advanced fibrosis via calculation. Specifically, any increase of TB independently increases the risk of 90-day transplantation free mortality in patients with cirrhosis. While, for patients with advanced fibrosis, only TB >12 mg/dL increased the risk. More importantly, based on the sufficient data of large prospective cohorts and rigorous analysis, we intuitively demonstrated the different effects of TB on the mortality in patients with cirrhosis and advanced fibrosis, and calculated their mathematical and clinical cutoffs for liver failure, respectively. The findings from this study offer an essential component of evidence-based ACLF diagnostic criteria in HBV high-endemic areas.
Western researchers represented by EASL-CLIF believe that the three major conditions of ACLF are cirrhosis, ADs and organ failure (). They did not think that ACLF will present in non-cirrhotic patients. In contrast, the Eastern researchers represented by APASL emphasize the “reversibility of ACLF” and exclude decompensated cirrhosis out of ACLF. To achieve a universally acceptable definition, the type of ACLF were suggested to be divided into three categories depending on underlying chronic liver diseases: type A (non-cirrhotic ACLF), type B (cirrhotic ACLF), and type C (decompensated cirrhotic ACLF) (, , ). However, these subjective concepts are not appropriate to serve as solid evidence.
A clear definition of liver failure has fundamental significance for the diagnosis of ACLF. From this perspective view, our findings were obtained from quantitative analysis of the data from large cohort studies, which provides the possibility to stop this controversy. At first, we revealed the different effects of TB on mortality in patients with cirrhosis and advanced fibrosis, respectively, and proved that liver failure can be diagnosed by TB alone in cirrhosis but not in advanced fibrosis. Therefore, we demonstrated our hypothesis that the controversy between the East and the West on how to use TB to diagnose liver failure was caused by differences of the study population. Then, in the comparison of the TB-mortality correlation curves of different underlying chronic liver diseases, we found that the trend of the curve of compensated cirrhosis was similar to that of decompensated cirrhosis and quite different from that of advanced fibrosis. We observed the saturation effects in both the two curves of cirrhosis, which didn't present in the curve of advanced fibrosis. On the other hand, when TB increases from 0 to 12 mg/dL, the curves of cirrhosis rises simultaneously while the curve of advanced fibrosis keeps horizontal. These findings suggest that the mechanism of liver failure in cirrhosis, whether compensated and decompensated, could be similar and the same criteria can be used for diagnosis. However, it does not support the view of APASL to exclude decompensated cirrhosis but use the same criteria to diagnose ACLF in compensated cirrhosis and non-cirrhotic chronic liver diseases.
The definition of TB cutoff for liver failure is controversial as well. Though various TB cutoffs have been proposed in relevant studies, they were all initialized from expert consensus or existing models. Actually, few studies illuminated the independent and quantitative correlation between TB level and the short-term mortality of patients. A clinically meaningful cutoff would be one particular value that correlates with a marked change in physiological response and patient outcome (). Thus, we calculated the TB cutoffs based on the mathematical definition (maximum of acceleration) and the clinical definition (15% 28-day transplantation-free mortality), respectively. In patients with cirrhosis, the two TB cutoffs are 14.2 mg/dL (mathematical) and 18.1 mg/dL (clinical), respectively, both the diagnosis rate (about one fifth) and the corresponding adjusted 28-day mortality (about 15%) were acceptable. In patients with advanced fibrosis, the mathematical TB cutoff is 12.1 mg/dL, whose corresponding mortality (2.9%) was much lower than the clinical definition (15%). In case the TB cutoff of clinical definition (36.0 mg/dL) was applied, only 1.3% patients can be diagnosed as liver failure. Therefore, from the perspective of high short-term mortality, liver failure in advanced fibrosis cannot be diagnosed by TB alone.
This study has several strengths. First, it is the unique study in demonstrating the independent and quantitative correlation between TB and short-term mortality in hospitalized patients with cirrhosis and advanced fibrosis, respectively. Based on the findings of the study, we proved that it is unfeasible to use the same criteria to diagnose liver failure in patients with cirrhosis and advanced fibrosis, settling this protracted controversy between the ACLF consortiums from East and West. Second, the TB cutoffs for liver failure were calculated completely based on mathematical methods, provide evidence-based reference for the establishment of ACLF diagnosis criteria. Third, the study based on the data of hospitalized patients with representative characteristics of cirrhosis and advanced in China, which implied that our findings could be applicable to the 2-billion-population HBV high-epidemic area (). Finally, the perspective multicenter design will result in low rates of loss to follow-up and missing variables, ensuring the reliability of our conclusions.
Several limitations should be acknowledged. First, we excluded the non-cirrhotic patients with a FIB-4 score <1.45. However, this strategy is implemented to rule-out the patients with merely mild or without fibrosis. The liver conditions of these patients are close to normal, whose features of liver failure (if presented) are similar to that of acute liver failure. Moreover, the 90-day mortality of these patients was only 1.1% (2/178), not the potential victims of ACLF. Second, we excluded the patients received LT within 90 days, which may have some potential inference on the results. However, taking transplant-free mortality as the primary outcome is a common practice in ACLF research to obtain the natural prognosis of patients.
Conclusion
This study is the first one to clearly demonstrate the different effects of TB on 90-day mortality in patients with cirrhosis and advanced fibrosis, proving that liver failure can be diagnosed by TB alone in cirrhosis but not in advanced fibrosis. We also proposed the first mathematical and clinical TB cutoffs (14.2 and 18.1 mg/dL in cirrhosis, and 12.1 and 36.0 mg/dL in advanced fibrosis) for liver failure via calculation. Our innovative work will become the foundation of the establishing evidence-based ACLF diagnostic criteria in HBV high-endemic areas.
Statements
Data availability statement
The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author/s at: aclf_group@163.com.
Ethics statement
The studies involving human participants were reviewed and approved by the Medical Ethics Board of Shanghai Renji Hospital. The patients/participants provided their written informed consent to participate in this study.
Author contributions
HL had full access to all the data used in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. HL: concept, design, and supervision. LQ and HL: drafting of the manuscript. WZ and HL: critical revision of the manuscript for important intellectual content. LQ and WZ: statistical analysis. HL, GD, XW, XZhe, YHu, JiC, ZM, YG, FL, and XL: obtained funding. All authors: acquisition of data, administrative, technical, or material support.
Funding
This work was supported by Grants from the National Science and Technology Major Project (2018ZX10302206, 2018ZX10723203, and 2017ZX10202202). It was partially supported by the National Key Research and Development Program of China (No. 2017YFC0908100 and 2017YFC0908103), Shanghai Hospital Development Commission (16CR1024B and SHDC2020CR1037B), Shanghai Municipal Education Commission–Guofeng Clinical Medicine and Shanghai Municipal Government Funding, the National Natural Science Foundation of China (82070650, 81271884, 81930061, 81401665, 81461130019, 81470038, 81470869, 81473641, 81900579, 81660333, 81670576, 81700561, 81870425, and GZ1263), the Foundation for Innovative Research groups of the Natural Science Foundation of Hubei Province of China (2018CFA031), and the Shandong Province Natural Science Foundation (No. ZR2019PH052).
Acknowledgments
We thank all the patients who participated in this study. We thank the following Chinese (Acute on) Chronic Liver Failure Consortium (Ch-CLIF.C) members and participants for their contributions to this study: Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University—Bo Zeng, Liuying Chen, Shijin Wang, Tongyu Wang, Fuchen Dong and Dandan Wu; Centre of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University— Yuxin Li, Yunyi Huang; Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University)— Jie Xia; Yi Zhou; Baoyan Xu; Shuning Sun, Yunjie Dan; Department of Infectious Disease, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University—Chengjin Liao, Xiaoxiao Liu; Department of Infectious Diseases, Institute of Infection and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology— Jing Liu, Ling Xu, Shue Xiong; Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University— Guotao Zhong, Congyan Zhu; Department of Hepatology, First Hospital of Jilin University— Chang Jiang, Xiaoyu Wen; Department of Infectious Disease, Taihe Hospital, Hubei University of Medicine—Qing Lei; Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Centre, Fudan University —Liujuan Ji, Jiefei Wang; Department of Infectious Diseases and Hepatology, Second Hospital of Shandong University—Xuanqiong Fang, Ziyu Wang; Liver Disease Centre, First Affiliated Hospital of Xinjiang Medical University—Fang, rong Jie, Nan Li; Department of Infectious Disease, Henan Provincial People's Hospital—Huiming Jin; Department of Infectious Diseases, Henan Provincial People's Hospital— Hai Li; Department of Infectious Diseases, Affiliated Hospital of Logistics University of People's Armed Police Force— Shaoyang Wang.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
MezzanoGJuanolaACardenasAMezeyEHamiltonJPPoseEet al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gut. (2021). 10.1136/gutjnl-2020-322161
2.
BajajJSO'LearyJGReddyKRWongFBigginsSWPattonHet al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology. (2014) 60:250–6. 10.1002/hep.27077
3.
KimTYSongDSKimHYSinnDHYoonELKimCWet al. Characteristics and discrepancies in acute-on-chronic liver failure: need for a unified definition. PLoS ONE. (2016) 11:e0146745. 10.1371/journal.pone.0146745
4.
MoreauRJalanRGinesPPavesiMAngeliPCordobaJet al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. (2013) 144:1426–37; 1437.e1421–9. 10.1053/j.gastro.2013.02.042
5.
SarinSKChoudhuryASharmaMKMaiwallRAl MahtabMRahmanSet al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. (2019) 13:353–90. 10.1007/s12072-019-09946-3
6.
WuTLiJShaoLXinJJiangLZhouQet al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut. (2018) 67:2181–91. 10.1136/gutjnl-2017-314641
7.
ChoudhuryAJindalAMaiwallRSharmaMKSharmaBCPamechaVet al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int. (2017) 11:461–71. 10.1007/s12072-017-9816-z
8.
ArroyoVMoreauRJalanRGinesPEASL-CLIF Consortium CANONIC Study. Acute-on-chronic liver failure: a new syndrome that will re-classify cirrhosis. J Hepatol. (2015) 62:S131–43. 10.1016/j.jhep.2014.11.045
9.
GustotTFernandezJGarciaEMorandoFCaraceniPAlessandriaCet al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. (2015) 62:243–52. 10.1002/hep.27849
10.
LiHChenLYZhangNNLiSTZengBPavesiMet al. Characteristics, diagnosis and prognosis of acute-on-chronic liver failure in cirrhosis associated to hepatitis B. Sci Rep. (2016) 6:25487. 10.1038/srep25487
11.
ShawcrossDLAustinMJAbelesRDMcPhailMJWYeomanADTaylorNJet al. The impact of organ dysfunction in cirrhosis: survival at a cost?J Hepatol. (2012) 56:1054–62. 10.1016/j.jhep.2011.12.014
12.
OlsonJCWendonJAKramerDJArroyoVJalanRGarcia-TsaoGet al. Intensive care of the patient with cirrhosis. Hepatology. (2011) 54:1864–72. 10.1002/hep.24622
13.
HernaezRSolaEMoreauRGinesP. Acute-on-chronic liver failure: an update. Gut. (2017) 66:541–53. 10.1136/gutjnl-2016-312670
14.
TrebickaJFernandezJPappMCaraceniPLalemanWGambinoCet al. The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology. J Hepatol. (2020) 10.1016/j.jhep.2020.11.012
15.
Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. (2018) 3:383–403. 10.1016/S2468-1253(18)30056-6
16.
SarinSKKumarMEslamMGeorgeJAl MahtabMAkbarSMFet al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. (2019) 5:167–228. 10.1016/S2468-1253(19)30342-5
17.
ShiYYangYHuYWuWYangQZhengMet al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology. (2015) 62:232–42. 10.1002/hep.27795
18.
MalinchocMKamathPSGordonFDPeineCJRankJter BorgPC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. (2000) 31:864–71. 10.1053/he.2000.5852
19.
JalanRPavesiMSalibaFAmorosAFernandezJHolland-FischerPet al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol. (2015) 62:831–40. 10.1016/j.jhep.2014.11.012
20.
BernalWJalanRQuagliaASimpsonKWendonJBurroughsA. Acute-on-chronic liver failure. Lancet. (2015) 386:1576–87. 10.1016/S0140-6736(15)00309-8
21.
SarinSKKumarAAlmeidaJAChawlaYKFanSTGargHet al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. (2009) 3:269–82. 10.1007/s12072-008-9106-x
22.
ChenTYangZChoudhuryAKAl MahtabMLiJChenYet al. Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region. Hepatol Int. (2019) 13:695–705. 10.1007/s12072-019-09992-x
23.
GuWYXuBYZhengXChenJWangXBHuangYet al. Acute-on-chronic liver failure in China: rationale for developing a patient registry and baseline characteristics. Am J Epidemiol. (2018) 187:1829–39. 10.1093/aje/kwy083
24.
QiaoLWangXDengGHuangYChenJMengZet al. Cohort profile: a multicentre prospective validation cohort of the Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study. BMJ open. (2021) 11:e037793. 10.1136/bmjopen-2020-037793
25.
MooreKPWongFGinesPBernardiMOchsASalernoFet al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. (2003) 38:258–66. 10.1053/jhep.2003.50315
26.
BleiATCordobaJPractice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol. (2001) 96:1968–76. 10.1111/j.1572-0241.2001.03964.x
27.
Vallet-PichardAMalletVNalpasBVerkarreVNalpasADhalluin-VenierVet al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection comparison with liver biopsy and fibrotest. Hepatology. (2007) 46:32–6. 10.1002/hep.21669
28.
KimWRBigginsSWKremersWKWiesnerRHKamathPSBensonJTet al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. (2008) 359:1018–26. 10.1056/NEJMoa0801209
29.
ChildCTurcotteJ. Surgery and portal hypertension. Major Probl Clin Surg. (1964) 1964:1–85.
30.
WoodS. Generalized Additive Models: An Introduction with R. Boca Raton, FL: Chapman & Hall (2006). 10.1201/9781420010404
31.
WoodSNAugustinNH. GAMs with integrated model selection using penalized regression splines and applications to environmental modelling. Ecol Modell. (2002) 157:157–77. 10.1016/S0304-3800(02)00193-X
32.
DeboeckPRNicholsonJKourosCLittleTDGarberJ. Integrating developmental theory and methodology: using derivatives to articulate change theories, models, and inferences. Appl Dev Sci. (2016) 19:217–31. 10.1080/10888691.2015.1021924
33.
JalanRYurdaydinCBajajJSAcharyaSKArroyoVLinHCet al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology. (2014) 147:4–10. 10.1053/j.gastro.2014.05.005
34.
BajajJSMoreauRKamathPSVargasHEArroyoVReddyKRet al. Acute-on-chronic liver failure: getting ready for prime time?Hepatology. (2018) 68:1621–32. 10.1002/hep.30056
35.
SpaiteDWHuCBobrowBJChikaniVSherrillDBarnhartBet al. Mortality and prehospital blood pressure in patients with major traumatic brain injury: implications for the hypotension threshold. JAMA Surg. (2017) 152:360–8. 10.1001/jamasurg.2016.4686
Summary
Keywords
liver failure, cutoff, quantitative analyse, short-term mortality, total bilirubin
Citation
Qiao L, Tan W, Wang X, Zheng X, Huang Y, Li B, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Shang J, Liu J, Yan H, Gu W, Zhang Y, Xiang X, Hou Y, Zhang Q, Xiong Y, Zou C, Chen J, Huang Z, Jiang X, Luo S, Chen Y, Gao N, Liu C, Yuan W, Mei X, Li J, Li T, Zheng R, Zhou X, Chen J, Deng G, Zhang W and Li H (2021) Different Effects of Total Bilirubin on 90-Day Mortality in Hospitalized Patients With Cirrhosis and Advanced Fibrosis: A Quantitative Analysis. Front. Med. 8:704452. doi: 10.3389/fmed.2021.704452
Received
03 May 2021
Accepted
14 May 2021
Published
23 June 2021
Volume
8 - 2021
Edited by
Yu-Chen Fan, Shandong University, China
Reviewed by
Yu Shi, Zhejiang University, China; Yubao Zheng, Third Affiliated Hospital of Sun Yat-sen University, China
Updates
Copyright
© 2021 Qiao, Tan, Wang, Zheng, Huang, Li, Meng, Gao, Qian, Liu, Lu, Shang, Liu, Yan, Gu, Zhang, Xiang, Hou, Zhang, Xiong, Zou, Chen, Huang, Jiang, Luo, Chen, Gao, Liu, Yuan, Mei, Li, Li, Zheng, Zhou, Chen, Deng, Zhang and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hai Li haili_17@126.comWeituo Zhang weituozhang@126.com
This article was submitted to Gastroenterology, a section of the journal Frontiers in Medicine
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.